Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Waldenström macroglobulinaemia: the key questions. Br J Haematol 2013 Aug;162(3):295-303

Date

05/09/2013

Pubmed ID

23651417

DOI

10.1111/bjh.12367

Scopus ID

2-s2.0-84880275386   4 Citations

Abstract

In this review, the key issues that pertain to Waldenström disease are discussed in a concise question-and-answer format. Diagnosis, prognosis, and indications for state-of-the-art therapy are updated. Current therapies presented at the 7th International Workshop for Waldenström Macroglobulinaemia are included.

Author List

D'Souza A, Ansell S, Reeder C, Gertz MA

Author

Anita D'Souza MD Associate Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antineoplastic Agents
Genetic Predisposition to Disease
Hematopoietic Stem Cell Transplantation
Humans
Prognosis
Risk Factors
Waldenstrom Macroglobulinemia
jenkins-FCD Prod-399 190a069c593fb5498b7fcd942f44b7bc9cdc7ea1